Dr. Reddy's (DRREDDY) | Financial Analysis & Statements
Dr. Reddy's Laboratories Ltd. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
87.3B
Gross Profit
46.8B
53.63%
Operating Income
14.3B
16.42%
Net Income
11.9B
13.63%
EPS (Diluted)
₹14.52
Balance Sheet Metrics
Total Assets
493.0B
Total Liabilities
155.8B
Shareholders Equity
337.2B
Debt to Equity
0.46
Cash Flow Metrics
Operating Cash Flow
27.8B
Free Cash Flow
10.8B
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dr. Reddy's Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 325.5B | 279.2B | 245.9B | 214.4B | 189.7B |
| Cost of Goods Sold | 135.1B | 115.6B | 106.5B | 100.6B | 86.6B |
| Gross Profit | 190.4B | 163.6B | 139.3B | 113.8B | 103.1B |
| Gross Margin % | 58.5% | 58.6% | 56.7% | 53.1% | 54.3% |
| Operating Expenses | |||||
| Research & Development | 27.4B | 22.9B | 19.4B | 17.5B | 16.5B |
| Selling, General & Administrative | 93.9B | 77.2B | 68.0B | 62.1B | 54.6B |
| Other Operating Expenses | -2.8B | -1.8B | -7.1B | -1.6B | -1.0B |
| Total Operating Expenses | 118.4B | 98.3B | 80.3B | 77.9B | 70.2B |
| Operating Income | 72.0B | 65.3B | 59.1B | 35.9B | 32.9B |
| Operating Margin % | 22.1% | 23.4% | 24.0% | 16.8% | 17.3% |
| Non-Operating Items | |||||
| Interest Income | 2.7B | 2.3B | 1.2B | 965.0M | 826.0M |
| Interest Expense | 2.8B | 1.7B | 1.4B | 958.0M | 970.0M |
| Other Non-Operating Income | 4.9B | 6.0B | 1.6B | -3.6B | -6.4B |
| Pre-tax Income | 76.8B | 71.9B | 60.4B | 32.3B | 26.4B |
| Income Tax | 19.5B | 16.2B | 15.3B | 8.7B | 9.2B |
| Effective Tax Rate % | 25.4% | 22.5% | 25.3% | 27.0% | 34.7% |
| Net Income | 57.2B | 55.7B | 45.1B | 23.6B | 17.2B |
| Net Margin % | 17.6% | 19.9% | 18.3% | 11.0% | 9.1% |
| Key Metrics | |||||
| EBITDA | 92.0B | 82.6B | 73.2B | 49.4B | 47.0B |
| EPS (Basic) | ₹67.89 | ₹66.93 | ₹54.29 | ₹28.42 | ₹20.79 |
| EPS (Diluted) | ₹67.79 | ₹66.80 | ₹54.17 | ₹28.34 | ₹20.73 |
| Basic Shares Outstanding | 832979820 | 831968515 | 830174450 | 829391892 | 829221700 |
| Diluted Shares Outstanding | 832979820 | 831968515 | 830174450 | 829391892 | 829221700 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Dr. Reddy's Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 14.7B | 7.1B | 5.8B | 14.9B | 14.8B |
| Short-term Investments | 43.3B | 74.4B | 56.0B | 29.5B | 19.7B |
| Accounts Receivable | 90.4B | 80.3B | 72.5B | 66.8B | 49.6B |
| Inventory | 71.1B | 63.6B | 48.7B | 50.9B | 45.4B |
| Other Current Assets | 4.0B | 2.8B | 5.2B | 3.3B | 4.1B |
| Total Current Assets | 250.1B | 248.0B | 204.3B | 181.9B | 148.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 3.0M | 3.0M | 0 | 0 |
| Goodwill | 120.4B | 45.5B | 39.3B | 36.1B | 44.8B |
| Intangible Assets | 96.8B | 37.0B | 30.8B | 27.2B | 35.6B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 20.6B | 15.4B | 10.0B | 8.5B | 10.9B |
| Total Non-Current Assets | 242.9B | 139.5B | 117.6B | 111.0B | 117.2B |
| Total Assets | 493.0B | 387.5B | 321.9B | 292.8B | 265.5B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 20.1B | 21.5B | 17.9B | 16.0B | 12.7B |
| Short-term Debt | 38.9B | 14.0B | 12.2B | 28.1B | 24.0B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 7.4B | 6.0B | 3.7B | 2.5B | 2.4B |
| Total Current Liabilities | 130.4B | 96.0B | 85.8B | 94.0B | 83.4B |
| Non-Current Liabilities | |||||
| Long-term Debt | 7.9B | 6.0B | 1.3B | 5.7B | 6.3B |
| Deferred Tax Liabilities | 14.1B | 909.0M | 833.0M | 60.0M | 338.0M |
| Other Non-Current Liabilities | 2.1B | 2.8B | 1.3B | 825.0M | 812.0M |
| Total Non-Current Liabilities | 25.4B | 10.9B | 5.0B | 8.3B | 9.0B |
| Total Liabilities | 155.8B | 107.0B | 90.9B | 102.3B | 92.4B |
| Equity | |||||
| Common Stock | 834.0M | 834.0M | 833.0M | 832.0M | 832.0M |
| Retained Earnings | 315.8B | 265.3B | 215.6B | 175.7B | 156.0B |
| Treasury Stock | 2.3B | 991.0M | 1.3B | 1.6B | 2.0B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 337.2B | 280.6B | 231.0B | 190.5B | 173.1B |
| Key Metrics | |||||
| Total Debt | 46.8B | 20.0B | 13.5B | 33.8B | 30.3B |
| Working Capital | 119.7B | 152.0B | 118.4B | 87.8B | 64.9B |
Balance Sheet Composition
Dr. Reddy's Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 57.2B | 55.7B | 45.1B | 23.6B | 17.2B |
| Depreciation & Amortization | 17.1B | 14.8B | 12.6B | 11.8B | 12.8B |
| Stock-Based Compensation | 424.0M | 407.0M | 397.0M | 592.0M | 584.0M |
| Working Capital Changes | -30.3B | -23.6B | -7.9B | -22.9B | -13.6B |
| Operating Cash Flow | 64.1B | 62.9B | 65.8B | 21.8B | 26.4B |
| Investing Activities | |||||
| Capital Expenditures | -27.0B | -15.3B | -11.2B | -14.3B | 85.0M |
| Acquisitions | -53.4B | -12.0M | 0 | -326.0M | -15.5B |
| Investment Purchases | -254.5B | -145.5B | -136.2B | -89.0B | -75.4B |
| Investment Sales | 279.6B | 129.8B | 112.8B | 77.8B | 79.5B |
| Investing Cash Flow | -55.3B | -31.1B | -34.6B | -25.8B | -11.3B |
| Financing Activities | |||||
| Share Repurchases | -1.4B | - | - | 0 | -1.2B |
| Dividends Paid | -6.7B | -6.6B | -5.0B | -4.1B | -4.1B |
| Debt Issuance | 0 | 3.8B | 0 | 0 | 3.8B |
| Debt Repayment | -1.3B | -4.9B | -1.0B | -785.0M | -4.5B |
| Financing Cash Flow | 22.4B | -1.5B | -25.0B | -1.1B | 1.0B |
| Free Cash Flow | 12.0B | 18.0B | 40.0B | 9.1B | 23.1B |
| Net Change in Cash | 31.2B | 30.4B | 6.2B | -5.1B | 16.1B |
Cash Flow Trend
Dr. Reddy's Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
19.40
Forward P/E
24.12
Price to Book
2.94
Price to Sales
3.17
PEG Ratio
-1.35
Profitability Ratios
Profit Margin
16.36%
Operating Margin
16.42%
Return on Equity
16.10%
Return on Assets
7.96%
Financial Health
Current Ratio
1.88
Debt to Equity
18.03
Beta
0.30
Per Share Data
EPS (TTM)
₹67.88
Book Value per Share
₹447.25
Revenue per Share
₹415.37
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| DRREDDY | 1.1T | 19.40 | 2.94 | 16.10% | 16.36% | 18.03 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Torrent | 1.4T | 61.35 | 16.50 | 25.18% | 17.83% | 33.40 |
| Lupin | 1.1T | 22.74 | 5.37 | 18.98% | 17.76% | 31.51 |
| Cipla | 1.1T | 23.20 | 3.20 | 16.85% | 16.26% | 1.42 |
Financial data is updated regularly. All figures are in the company's reporting currency.





